At-home Bleaching Using Clear Retainers
PATIENT SATISFACTION WITH AT-HOME DENTAL BLEACHING USING VIVERA OR ESSIX RETAINERS: A RANDOMIZED CLINICAL TRIAL
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Isabel Giráldez, PhD
- Phone Number: +34669119781
- Email: isabel.giraldez@urjc.es
Study Locations
-
-
Navarre
-
Tafalla, Navarre, Spain, 31300
- Clínica Dental Iturralde
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
The inclusion criteria will be the following:
- Patients over 18 years of age.
- Patients with vital teeth without restorations, single crowns, implants and/or bridges at the level of the anterior teeth.
- Absence of cavities in the teeth to be whitened.
- Patients with satisfactory oral hygiene, and periodontally healthy, who are not undergoing periodontal maintenance and who do not use chlorhexidine rinses. Patients with recessions without sensitivity are included.
- Absence of sensitivity, measured based on stimulation with the air from the syringe.
- Patients who are at least in A2-A3 color (Vita Classic Guide)
The exclusion criteria will be the following:
- Patients who have previously undergone whitening (less than 5 years).
- Patients undergoing orthodontic treatment.
- Patients with white spot or developmental alterations (dentinogenesis imperfecta, amelogenesis imperfecta) or with stains (tetracyclines or fluorosis).
- Patients with a history of trauma to anterior teeth.
- Patients who require internal whitening.
- Smokers.
- Pregnant or lactating women.
- Allergy to any component of whitening.
- Alterations of the oral mucosa (desquamative gingivitis, OLP, leukoplakias, etc.).
- Medical conditions considered by the researchers that may compromise the study or the individual safety of the patient.
- Patients with poor oral hygiene.
- Patients with previous hypersensitivity.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Essix-type retairner
Two simple randomizations will be performed using a software program freely available online (www.sealedenvelop.com).
For the first randomization, for each participant, the group (type of tray) will be randomized and it will always be applied to the participant's right hemiarch (n=40) according to the model: essix-type retairner or Vivera retainer.
Subsequently, the second randomization will be carried out, which will define the alternate days for the use of essix-type retairner and Vivera retainer: Monday, Wednesday and Friday or Tuesday, Thursday and Saturday.
|
Two syringes of 10% carbamide peroxide bleaching gel will be provided for use with each type of tray.
Volunteers will be instructed to use the whitening gel once a day for 2 hours, for 3 days per week with each retainer, completing a total of 4 weeks of whitening procedure.
|
|
Active Comparator: Vivera retainer
The patients will use the clear aligner on their right hemiarch and according to the second randomization it will be applied on Monday, Wednesday and Friday or Tuesday, Thursday and Saturday.
|
Two syringes of 10% carbamide peroxide bleaching gel will be provided for use with each type of tray.
Volunteers will be instructed to use the whitening gel once a day for 2 hours, for 3 days per week with each retainer, completing a total of 4 weeks of whitening procedure.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient´s satisfaction
Time Frame: Baseline, after one, two and four weeks
|
It will be measured with a questionnaire using a visual analog scale (EVA), when a essix-type retairner or Vivera retainer is used to perform a at home bleaching treatment with 10% carbamide peroxide.
|
Baseline, after one, two and four weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Color change evaluation
Time Frame: Baseline, after one, two and four weeks
|
The color will be assesed using subjetive color guides (VITA Classical and VITA 3D-MASTER) and a objetive digital spectrophotometer (VITA Easyshade).
|
Baseline, after one, two and four weeks
|
|
Intensity and absolute risk of tooth sensitivity
Time Frame: Baseline, after one, two, four weeks, and at 1 month after bleaching treatment
|
They will be determined by means of a visual analog scale (EVA), using a essix-type retairner or Vivera retainer, during at home bleaching treatment with 10% carbamide peroxide.
|
Baseline, after one, two, four weeks, and at 1 month after bleaching treatment
|
|
Intensity and absolute risk of gingival irritation
Time Frame: Baseline, after one, two, four weeks, and at 1 month after bleaching treatment
|
They will be determined by means of a visual analog scale (EVA), using a essix-type retairner or Vivera retainer, during at home bleaching treatment with 10% carbamide peroxide.
|
Baseline, after one, two, four weeks, and at 1 month after bleaching treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
General Publications
- Almeida LC, Riehl H, Santos PH, Sundfeld ML, Briso AL. Clinical evaluation of the effectiveness of different bleaching therapies in vital teeth. Int J Periodontics Restorative Dent. 2012 Jun;32(3):303-9.
- Carneiro TS, Favoreto MW, Bernardi LG, Sutil E, Wendlinger M, Centenaro GG, Reis A, Loguercio AD. Gingival irritation in patients submitted to at-home bleaching with different cutouts of the bleaching tray: a randomized, single-blind clinical trial. Clin Oral Investig. 2022 Jun;26(6):4381-4390. doi: 10.1007/s00784-022-04401-4. Epub 2022 Feb 7.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- URJC_IDIBO_1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.